Lysosomal modulatory drugs for a broad strategy against protein accumulation disorders

Current Alzheimer Research

Volumn 6, Issue 5, 2009, Pages 438-445

  Bahr, Ben A ^a,b,c  

^a UNIVERSITY OF CONNECTICUT   (United States)

^b UNIVERSITY OF NORTH CAROLINA AT PEMBROKE   (United States)

^c NORTHEASTERN UNIVERSITY   (United States)

Author keywords

Alzheimer's disease; Cathepsin; Hippocampal slice culture; Lysosomal enhancement; Lysosome modulation; PADK; Synaptic decline

Indexed keywords

ASPARTIC PROTEINASE INHIBITOR; BENZYLOXYCARBONYLPHENYLALANYLALANYLDIAZOMETHYLKETONE; CATHEPSIN; CHLOROQUINE; DIAZOACETYL DEXTRO LEVO 2 AMINOHEXANOIC ACID METHYL ESTER; LYSOSOME ENZYME; PEPTIDE DERIVATIVE; TAU PROTEIN; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; BRAIN REGION; CELL STRUCTURE; CONFERENCE PAPER; FRONTOTEMPORAL DEMENTIA; GLYCOSYLATION; HIPPOCAMPUS; HUMAN; LYSOSOME MEMBRANE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEFICIENCY; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FOLDING; PROTEIN PHOSPHORYLATION; PROTEIN SECRETION; PROTEIN SYNTHESIS; SYNAPTIC MEMBRANE;

ALZHEIMER DISEASE; ANIMALS; CATHEPSINS; HIPPOCAMPUS; HUMANS; LYSOSOMES; NEUROFIBRILLARY TANGLES; PHOSPHORYLATION; TAU PROTEINS;

EID: 70249092882     PISSN: 15672050     EISSN: None     Source Type: Journal    
DOI: 10.2174/156720509789207903     Document Type: Conference Paper

References (93)

1. Suzuki N, Cheung TT, Cai XD, Odaka A, Otvos L Jr, Eckman C, et al. An increased percentage of long amyloid beta protein secreted by familial amyloid beta protein precursor (beta APP717) mutants. Science 264: 1336-1340 (1994). (Pubitemid 24219086)
2. Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: Progress and problems on the road to therapeutics. Science 297: 353-1256 (2002). (Pubitemid 34790756)
3. Bahr BA. Dysfunction and activation of the lysosomal system: Implications for and against Alzheimer's disease. In 'Focus on Alzheimer's Disease Research' (Ed: Welsh EM), Nova Biomedical Books, New York, pp. 115-149 (2003).
4. Bahr BA, Hoffman KB, Yang AJ, Hess US, Glabe CG, Lynch G. Amyloid β protein is internalized selectively by hippocampal field CA1 and causes neurons to accumulate amyloidogenic carboxyterminal fragments of the amyloid precursor protein. J Comp Neurol 397: 139-147 (1998). (Pubitemid 28304057)
5. Walsh DM, Tseng BP, Rydel RE, Podlisny MB, Selkoe DJ. The oligomerization of amyloid beta-protein begins intracellularly in cells derived from human brain. Biochemistry 39: 10831-10839 (2000).
6. Zhang Y, McLaughlin R, Goodyer C, LeBlanc A. Selective cytotoxicity of intracellular amyloid β peptide 1-42 through p53 and Bax in cultured primary human neurons. J Cell Biol 156: 519-529 (2002). (Pubitemid 34839899)
7. Esposito L, Gan L, Yu GQ, Essrich C, Mucke L. Intracellularly generated amyloid-beta peptide counteracts the antiapoptotic function of its precursor protein and primes proapoptotic pathways for activation by other insults in neuroblastoma cells. J Neurochem 91: 1260-1274 (2004). (Pubitemid 39658553)
8. Kawarabayashi T, Shoji M, Younkin LH, Wen-Lang L, Dickson DW, Murakami T, et al. Dimeric amyloid beta protein rapidly accumulates in lipid rafts followed by apolipoprotein E and phosphorylated tau accumulation in the Tg2576 mouse model of Alzheimer's disease. J Neurosci 24: 3801-3809 (2004). (Pubitemid 38509410)
9. Takahashi RH, Almeida CG, Kearney PF, Yu F, Lin MT, Milner TA, et al. Oligomerization of Alzheimer's beta-amyloid within processes and synapses of cultured neurons and brain. J Neurosci 24: 3592-3599 (2004). (Pubitemid 38481116)
10. Oddo S, Caccamo A, Tran L, Lambert MP, Glabe CG, Klein WL, et al. Temporal profile of amyloid-β (Aβ) oligomerization in an in vivo model of Alzheimer disease. J Biol Chem 281: 1599-1604 (2006).
11. Lambert MP, Barlow AK, Chromy BA, Edwards C, Freed R, Liosatos M, et al. Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. Proc Natl Acad Sci USA 95: 6448-6453 (1998). (Pubitemid 28249033)
12. Walsh DM, Klyubin I, Fadeeva JV, Cullen WK, Anwyl R, Wolfe MS, et al. Naturally secreted oligomers of amyloid β protein potently inhibit hippocampal long-term potentiation in vivo. Nature 416: 535-539 (2002). (Pubitemid 34288854)
13. Bendiske J, Bahr BA. Lysosomal activation is a compensatory response against protein accumulation and associated synaptopathogenesis - an approach for slowing Alzheimer's disease? J Neuropathol Exp Neurol 62: 451-463 (2003).
14. Cleary JP, Walsh DM, Hofmeister JJ, Shankar GM, Kuskowski MA, Selkoe DJ, et al. Natural oligomers of the amyloid-beta protein specifically disrupt cognitive function. Nature Neurosci 8: 79-84 (2005).
15. Lesné S, Koh MT, Kotilinek L, Kayed R, Glabe CG, Yang A, et al. A specific amyloid-β protein assembly in the brain impairs memory. Nature 440: 352-357 (2006).
16. Lacor PN, Buniel MC, Furlow PW, Clemente AS, Velasco PT, Wood M, et al. Abeta oligomer-induced aberrations in synapse composition, shape and density provide a molecular basis for loss of connectivity in Alzheimer's disease. J Neurosci 27: 796-807 (2007). (Pubitemid 46174498)
17. 1-40 attenuates synaptic AMPA receptor function. Synapse 61: 367-374 (2007).
18. Shankar GM, Bloodgood BL, Townsend M, Walsh DM, Selkoe DJ, Sabatini BL. Natural oligomers of the Alzheimer amyloid-beta protein induce reversible synapse loss by modulating an NMDA-type glutamate receptor-dependent signaling pathway. J Neurosci 27: 2866-2875 (2007). (Pubitemid 46438992)
19. Hardy J, Duff K, Hardy KG, Perez-Tur J, Hutton M. Genetic dissection of Alzheimer's disease and related dementias: Amyloid and its relationship to tau. Nat Neurosci 1: 355-358 (1998).
20. Lee VM, Goedert M, Trojanowski JQ. Neurodegenerative tauopathies. Annu Rev Neurosci 24: 1121-1159 (2001).
21. Cairns NJ, Bigio EH, Mackenzie IR, Neumann M, Lee VM, Hatanpaa KJ, et al. Neuropathologic diagnostic and nosologic criteria for frontotemporal lobar degeneration: Consensus of the Consortium for Frontotemporal Lobar Degeneration. Acta Neuropathol 114: 5-22 (2007). (Pubitemid 47029055)
22. Neumann M, Sampathu DM, Kwong LK, Truax AC, Micsenyi MC, Chou TT, et al. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science 314: 130-133 (2006). (Pubitemid 44547757)
23. Lin WL, Dickson DW. Ultrastructural localization of TDP-43 in filamentous neuronal inclusions in various neurodegenerative diseases. Acta Neuropathol 116: 205-213 (2008).
24. Nalivaeva NN, Fisk LR, Belyaev ND, Turner AJ. Amyloid-degrading enzymes as therapeutic targets in Alzheimer's disease. Curr Alzheimer Res 5: 212-224 (2008).
25. Stoppini L, Buchs PA, Muller D. A simple method for organotypic cultures of nervous tissue. J Neurosci Methods 37: 173-182 (1991).
26. Bahr BA, Kessler M, Rivera S, Vanderklish PW, Hall RA, Singh Mutneja M, et al. Stable maintenance of glutamate receptors and other synaptic components in long-term hippocampal slices. Hippocampus 5: 425-439 (1995). (Pubitemid 26088280)
27. Bahr BA. Long-term hippocampal slices: a model system for investigating synaptic mechanisms and pathologic processes. J Neurosci Res 42: 294-305 (1995).
28. Blaabjerg M, Kristensen BW, Bonde C, Zimmer J. The metabotropic glutamate receptor agonist 1S,3R-ACPD stimulates and modulates NMDA receptor mediated excitotoxicity in organotypic hippocampal slice cultures. Brain Res 898: 91-104 (2001). (Pubitemid 32274196)
29. Hoffman KB, Murray BA, Lynch G, Munirathinam S, Bahr BA. Delayed and isoform-specific effect of NMDA exposure on neural cell adhesion molecules in hippocampus. Neurosci Res 39: 167-173 (2001). (Pubitemid 32153893)
30. Vornov JJ, Tasker RC, Coyle JT. Delayed protection by MK-801 and tetrodotoxin in a rat organotypic hippocampal culture. Stroke 25: 457-464 (1994).
31. Caba E, Bahr BA. Biphasic activation of NF-kB in the excitotoxic hippocampus. Acta Neuropathol 108: 173-182 (2004). (Pubitemid 39199507)
32. Bonde C, Noraberg J, Noer H, Zimmer J. Ionotropic glutamate receptors and glutamate transporters are involved in necrotic neuronal cell death induced by oxygen-glucose deprivation of hippocampal slice cultures. Neuroscience 136: 779-794 (2005). (Pubitemid 41774724)
33. Karanian DA, Baude A, Brown QB, Parsons C, Bahr BA. 3-Nitropropionic acid toxicity in hippocampus: Protection through N-methyl-D-aspartate receptor antagonism. Hippocampus 16: 834-842 (2006). (Pubitemid 44650901)
34. Bahr BA, Abai B, Gall CM, Vanderklish PW, Hoffman KB, Lynch G. Induction of β-amyloid-containing polypeptides in hippocampus: evidence for a concomitant loss of synaptic proteins and interactions with an excitotoxin. Exp Neurol 129: 81-94 (1994). (Pubitemid 2146656)
35. Takauchi S, Miyoshi K. Cytoskeletal changes in rat cortical neurons induced by long-term intraventricular infusion of leupeptin. Acta Neuropathol 89: 8-16 (1995).
36. Mielke JG, Murphy MP, Maritz J, Bengualid KM, Ivy GO. Chloroquine administration in mice increases β-amyloid immunoreactivity and attenuates kainate-induced blood-brain barrier dysfunction. Neurosci Lett 227: 169-172 (1997). (Pubitemid 27243970)
37. Oyama F, Murakami N, Ihara Y. Chloroquine myopathy suggests that tau is degraded in lysosomes: Implication for the formation of paired helical filaments in Alzheimer's disease. Neurosci Res 31: 1-8 (1998). (Pubitemid 28325592)
38. Bendiske J, Caba E, Brown QB, Bahr BA. Intracellular deposition, microtubule destabilization, and transport failure: An 'early' pathogenic cascade leading to synaptic decline. J Neuropathol Exp Neurol 61: 640-650 (2002).
39. Butler D, Brown QB, Chin DJ, Batey L, Karim S, Mutneja MS, et al. Cellular responses to protein accumulation involve autophagy and lysosomal enzyme activation. Rejuvenation Res 8: 227-237 (2005). (Pubitemid 41814344)
40. Kenessey A, Nacharaju P, Ko LW, Yen SH. Degradation of tau by lysosomal enzyme cathepsin D: Implication for Alzheimer neurofibrillary degeneration. J Neurochem 69: 2026-2038 (1997). (Pubitemid 27452750)
41. Ikeda K, Akiyama H, Arai T, Kondo H, Haga C, Tsuchiya K, et al. Neurons containing Alz-50-immunoreactive granules around the cerebral infarction: Evidence for the lysosomal degradation of altered tau in human brain? Neurosci Lett 284: 187-189 (2000).
42. Bi X, Haque TS, Zhou J, Skillman AG, Lin B, Lee CE, et al. Novel cathepsin D inhibitors block the formation of hyperphosphorylated tau fragments in hippocampus. J Neurochem 74: 1469-1477 (2000). (Pubitemid 30163967)
43. Benowitz LI, Rodriguez W, Paskevich P, Mufson EJ, Schenk D, Neve RL. The amyloid precursor protein is concentrated in neuronal lysosomes in normal and Alzheimer disease subjects. Exp Neurol 106: 237-250 (1989). (Pubitemid 20011225)
44. Nixon RA, Mathews PM, Cataldo AM, Mohan PS, Schmidt SD, Duff K, et al. In vivo perturbation of lysosomal function promotes neurodegeneration in the PS1 M146V/APP K670N,M671L mouse model of Alzheimer's disease pathology. In 'Alzheimer's Disease: Advances in Etiology, Pathogenesis and Therapeutics' (Eds: Iqbal K, Sisodia SS and Winblad B), John Wiley & Sons, New York, pp. 687-696 (2001).
45. Butler D, Nixon RA, Bahr BA. Potential compensatory responses through autophagic/lysosomal pathways in neurodegenerative diseases. Autophagy 2: 234-237 (2006). (Pubitemid 44030894)
46. Ryzhikov S, Bahr BA. Gephyrin alterations due to protein accumulation stress are reduced by the lysosomal modulator Z-Phe-Aladiazomethylketone. J Mol Neurosci 34: 131-139 (2008). (Pubitemid 351903616)
47. Hempen B, Brion JP. Reduction of acetylated α-tubulin immunoreactivity in neurofibrillary tangle-bearing neurons in Alzheimer's disease. J Neuropathol Exp Neurol 55: 964-972 (1996). (Pubitemid 126449410)
48. Sahara N, Tomiyama T, Mori H. Missense point mutations of tau to segregate with FTDP-17 exhibit site-specific effects on microtubule structure in COS cells: A novel action of R406W mutation. J Neurosci Res 60: 380-387 (2000). (Pubitemid 30253602)
49. Pérez M, Lim F, Arrasate M, Avila J. The FTDP-17-linked mutation R406W abolishes the interaction of phosphorylated tau with microtubules. J Neurochem 74: 2583-2589 (2000). (Pubitemid 30314236)
50. Rosenmann H, Grigoriadis N, Eldar-Levy H, Avital A, Rozenstein L, Touloumi O, et al. A novel transgenic mouse expressing double mutant tau driven by its natural promoter exhibits tauopathy characteristics. Exp Neurol 212: 71-84 (2008).
51. Mucke L, Masliah E, Yu GO, Mallory M, Rockenstein EM, Tatsuno G, et al. High level neuronal expression of Aβ 1-42 in wild-type human amyloid protein precursor transgenic mice: Synaptotoxicity without plaque formation. J Neurosci 20: 4050-4058 (2000).
52. Stokin GB, Lillo C, Falzone TL, Brusch RG, Rockenstein E, Mount SL, et al. Axonopathy and transport deficits early in the pathogenesis of Alzheimer's disease. Science 307: 1282-1288 (2005). (Pubitemid 40299973)
53. Mocanu MM, Nissen A, Eckermann K, Khlistunova I, Biernat J, Drexler D, et al. The potential for beta-structure in the repeat domain of tau protein determines aggregation, synaptic decay, neuronal loss, and coassembly with endogenous tau in inducible mouse models of tauopathy. J Neurosci 28: 737-748 (2008). (Pubitemid 351159036)
54. Bahr BA, Bendiske J. Neuropathogenic contributions of lysosomal dysfunction. J Neurochem 83: 481-489 (2002).
55. Kanju PM, Parameshwaran K, Vaithianathan T, Sims CM, Huggins K, Bendiske J, et al. Lysosomal dysfunction produces distinct alterations in synaptic α-amino-3-hydroxy-5-methylisoxazole-propionic acid and N-methyl-D-aspartate receptor currents in hippocampus. J Neuropathol Exp Neurol 66: 779-788 (2007). (Pubitemid 47360953)
56. Butler D, Bendiske J, Michaelis ML, Karanian DA, Bahr BA. Microtubule-stabilizing agent prevents protein accumulation-induced loss of synaptic markers. Eur J Pharmacol 562: 20-27 (2007). (Pubitemid 46466756)
57. Ferrari-Toninelli G, Bonini SA, Bettinsoli P, Uberti D, Memo M. Microtubule stabilizing effect of notch activation in primary cortical neurons. Neuroscience 154: 946-952 (2008).
58. Callahan LM, Coleman PD. Neurons bearing neurofibrillary tangles are responsible for selected synaptic deficits in Alzheimer's disease. Neurobiol Aging 16: 311-314 (1995).
59. Callahan LM, Chow N, Cheetham JE, Cox C, Coleman PD. Analysis of message expression in single neurons of Alzheimer's disease brain. Neurobiol Aging 19: 99-105 (1998). (Pubitemid 28178947)
60. Callahan LM, Vaules WA, Coleman PD. Quantitative decrease in synaptophysin message expression and increase in cathepsin D message expression in Alzheimer disease neurons containing neurofibrillary tangles. J Neuropathol Exp Neurol 58: 275-287 (1999).
61. Shankar GM, Li S, Mehta TH, Garcia-Munoz A, Shepardson NE, Smith I, et al. Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat Med 14: 837-842 (2008).
62. Lue LF, Kuo YM, Roher AE, Brachova L, Shen Y, Sue L, et al. Soluble amyloid beta peptide concentration as a predictor of synaptic change in Alzheimer's disease. Am J Pathol 155: 853-862 (1999). (Pubitemid 29426831)
63. Coleman P, Federoff H, Kurlan R. A focus on the synapse for neuroprotection in Alzheimer disease and other dementias. Neurology 63: 1155-1162 (2004). (Pubitemid 39350010)
64. Yoshiyama Y, Higuchi M, Zhang B, Huang SM, Iwata N, Saido TC, et al. Synapse loss and microglial activation precede tangles in a P301S tauopathy mouse model. Neuron 53: 337-351 (2007). (Pubitemid 46161268)
65. Banay-Schwartz M, DeGuzman T, Kenessey A, Palkovits M, Lajtha A. The distribution of cathepsin D activity in adult and aging human brain regions. J Neurochem 58: 2207-2211 (1992).
66. Haas U, Sparks DL. Cortical cathepsin D activity and immunolocalization in Alzheimer disease, critical coronary artery disease, and aging. Mol Chem Neuropathol 29: 1-14 (1996). (Pubitemid 26327478)
67. Jung H, Lee EY, Lee SI. Age-related changes in ultrastructural features of cathepsin B- and D-containing neurons in rat cerebral cortex. Brain Res 844: 43-54 (1999). (Pubitemid 29490951)
68. Nakanishi H. Neuronal and microglial cathepsins in aging and age-related diseases. Ageing Res Rev 2: 367-381 (2003). (Pubitemid 37159399)
69. Pentchev PG, Gal AE, Booth AD, Omodeo-Sale F, Fouks J, Neumeyer BA, et al. A lysosomal storage disorder in mice characterized by a dual deficiency of sphingomyelinase and glucocerebrosidase. Biochim Biophys Acta 619: 669-679 (1980).
70. Sleat DE, Sohar I, Pullarkat PS, Lobel P, Pullarkat RK. Specific alterations in levels of mannose 6-phosphorylated glycoproteins in different neuronal ceroid lipofuscinoses. Biochem J 334: 547-551 (1998). (Pubitemid 28457200)
71. Nixon RA, Mathews PM, Cataldo AM. The neuronal endosomal-lysosomal system in Alzheimer's disease. J Alzheimers Dis 3: S97-107 (2001).
72. Mueller-Steiner S, Zhou Y, Roberson ED, Sun B, Chen J, Wang X, et al. Antiamyloidogenic and neuroprotective functions of cathepsin B: Implications for Alzheimer's disease. Neuron 51: 703-714 (2006). (Pubitemid 44374903)
73. Lim F, Hernández F, Lucas JJ, Gómez-Ramos P, Morán MA, Avila J. FTDP-17 mutations in tau transgenic mice provoke lysosomal abnormalities and tau filaments in forebrain. Mol Cell Neurosci 18: 702-714 (2001). (Pubitemid 34060150)
74. Cataldo AM, Barnett JL, Berman SA, Li J, Quarless S, Bursztajn S, et al. Gene expression and cellular content of cathepsin D in Alzheimer's disease brain: evidence for early up-regulation of the endosomal-lysosomal system. Neuron 14: 671-680 (1995).
75. Smith MA, Richey PL, Kalaria RN, Perry G. Elastase is associated with the neurofibrillary pathology of Alzheimer disease: a putative link between proteolytic imbalance and oxidative stress. Restorative Neurol Neurosci 9: 213-217 (1996). (Pubitemid 26227969)
76. Lemere CA, Munger JS, Shi GP, Natkin L, Haass C, Chapman HA, et al. The lysosomal cysteine protease, cathepsin S, is increased in Alzheimer's disease and Down syndrome brain. An immunocytochemical study. Am J Pathol 146: 848-860 (1995).
77. Yang AJ, Chandswangbhuvana D, Margol L, Glabe CG. Loss of endosomal/lysosomal membrane impermeability is an early event in amyloid Abeta1-42 pathogenesis. J Neurosci Res 52: 691-698 (1998). (Pubitemid 28300049)
78. McKee AC, Carreras I, Hossain L, Ryu H, Klein WL, Oddo S, et al. Ibuprofen reduces Abeta, hyperphosphorylated tau and memory deficits in Alzheimer mice. Brain Res 1207: 225-236 (2008).
79. Li Y, Xu C, Schubert D. The up-regulation of endosomallysosomal components in amyloid β-resistant cells. J Neurochem 73: 1477-1482 (1999). (Pubitemid 29440148)
80. Qin ZH, Wang Y, Kegel KB, Kazantsev A, Apostol BL, Thompson LM, et al. Autophagy regulates the processing of amino terminal huntingtin fragments. Hum Mol Genet 12: 3231-3244 (2003). (Pubitemid 37541069)
81. Lee HJ, Khoshaghideh F, Patel S, Lee SJ. Clearance of α-synuclein oligomeric intermediates via the lysosomal degradation pathway. J Neurosci 24: 1888-1896 (2004).
82. Collins PR, Stack CM, O'Neill SM, Doyle S, Ryan T, Brennan GP, et al. Cathepsin L1, the major protease involved in liver fluke virulence: Propeptide cleavage sites and autoactivation of the zymogen secreted from gastrodermal cells. J Biol Chem 279: 17038-17046 (2004). (Pubitemid 38560458)
83. Fuchs D, Berges C, Opelz G, Daniel V, Naujokat C. Increased expression and altered subunit composition of proteasomes induced by continuous proteasome inhibition establish apoptosis resistance and hyperproliferation of Burkitt lymphoma cells. J Cell Biochem 103: 270-283 (2008).
84. Weisberg E, Griffin JD. Mechanism of resistance to the ABL tyrosine kinase inhibitor STI571 in BCR/ABL-transformed hematopoietic cell lines. Blood 95: 3498-3505 (2000). (Pubitemid 30428483)
85. Deininger M. Resistance to imatinib: Mechanisms and management. J Natl Compr Cancer Network 3: 757-768 (2005).
86. Sigmond J, Backus HH, Wouters D, Temmink OH, Jansen G, Peters GJ. Induction of resistance to the multitargeted antifolate Pemetrexed (ALIMTA) in WiDr human colon cancer cells is associated with thymidylate synthase overexpression. Biochem Pharmacol 66: 431-438 (2003). (Pubitemid 36937028)
87. Tekle C, Giovannetti E, Sigmond J, Graff JR, Smid K, Peters GJ. Molecular pathways involved in the synergistic interaction of the PKC beta inhibitor enzastaurin with the antifolate pemetrexed in non-small cell lung cancer cells. Br J Cancer 99: 750-759 (2008).
88. Sun B, Zhou Y, Halabisky B, Lo I, Cho SH, Mueller-Steiner S, et al. Cystatin C-cathepsin B axis regulates amyloid β levels and associated neuronal deficits in an animal model of Alzheimer's disease. Neuron 60:247-257 (2008).
89. Hook VY, Reisine TD. Cysteine proteases are the major β-secretase in the regulated secretory pathway that provides most of the β-amyloid in Alzheimer's disease: role of BACE 1 in the constitutive secretory pathway. J Neurosci Res 74:393-405 (2003).
90. Hook V, Toneff T, Bogyo M, Greenbaum D, Medzihradszky KF, Neveu J, et al. Inhibition of cathepsin B reduces β-amyloid production in regulated secretory vesicles of neuronal chromaffin cells: Evidence for cathepsin B as a candidate β-secretase of Alzheimer's disease. Biol Chem 386: 931-940 (2005). (Pubitemid 41448149)
91. Hook VY, Kindy M, Hook G. Inhibitors of cathepsin B improve memory and reduce β-amyloid in transgenic Alzheimer disease mice expressing the wild-type, but not the Swedish mutant, β-secretase site of the amyloid precursor protein. J Biol Chem 283:7745-7753 (2008).
92. Klein DM, Felsenstein KM, Brenneman DE. Cathepsins B and L differentially regulate amyloid precursor protein processing. J Pharmacol Exp Ther, in press (2009).
93. Felbor U, Kessler B, Mothes W, Goebel HH, Ploegh HL, Bronson RT, et al. Neuronal loss and brain atrophy in mice lacking cathepsins B and L. Proc Natl Acad Sci USA 99: 7883-7888 (2002). (Pubitemid 34650974)